Teva Pharmaceuticals’ (NYSE: TEVA) first quarter 2020 results beat consensus estimates. The drugmaker reported adjusted earnings of $0.76 per share on revenue of $4.4 billion. Wall Street expected Teva to earn $0.59 per share on revenue of $4.15 billion. TEVA stock surged about 7% in the pre-market trading session.
GAAP net income attributable to ordinary shareholders was $69 million or $0.06 per share in the first quarter of 2020, compared to GAAP net loss of $105 million or $0.10 per share in the first quarter of 2019.
The Tel Aviv, Israel-based company confirmed its outlook for fiscal 2020. EPS is expected to be between $2.30 and $2.55, while revenue is targeted to be in the range of $16.6 billion to $17 billion for fiscal 2020.
Adobe, Inc. (NASDAQ: ADBE) has been dominating the design software space for quite some time, all along staying resilient to macroeconomic fluctuations and market headwinds. The company’s cloud-based applications, offered
Brilliant Earth IPO: Here are a few points to note about this jewelry company that goes public next week
Jewelry has always played a significant role in people’s lives. As life begins to go back to normal after the pandemic and people start attending social events, they are looking
Tell us about BioCloud, how it’s different from any alternate existing products, and your distribution model. BioCloud exists as a part of Kontrol Technologies and is an innovation within our